-
Product Name
Tezepelumab reference antibody
- Documents
-
Description
Anti-TSLP Antibody (Tezepelumab)
-
Tested applications
ELISA
-
Species reactivity
Human TSLP
-
Isotype
IgG2
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-TSLP Antibody (tezepelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-TSLP Antibody (tezepelumab) is 98.64%, determined by SEC-HPLC.
Bioactivity: ELISA
Immobilized human TSLP His at 2 ug/mL can bind Anti-TSLP Antibody (tezepelumab), EC50=0.0518 ug/mL.
Function: Blocking
Anti-TSLP Antibody (tezepelumab)-induced FACS Blocking activity was evaluated using TSLPR/IL7R-CHO-K. The IC50 was approximately 0.0802 ug/mL.
Research in vivo
Tezepelumab reduced levels of IL13 in BALF of OVA asthma model on B-hTSLP/hTSLPR mice. The result showed significant IL13 inhibition effects at 15 mpk.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"